NVAX vs. MRNA

In the year-to-date period, NVAX achieves a -21.77% return, which is significantly higher than MRNA's -43.12% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Novavax, Inc. (NVAX) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NVAX Sharpe Ratio is -0.55, which is higher than the MRNA Sharpe Ratio of -1.18. The chart below compares the historical Sharpe Ratios of NVAX and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither NVAX nor MRNA has paid dividends to shareholders.

The maximum NVAX drawdown since its inception was -98.82%, roughly equal to the maximum MRNA drawdown of -95.12%. Use the drawdown chart below to compare losses from any high point for NVAX and MRNA. For additional features, visit the drawdowns tool.

Novavax, Inc. (NVAX) has a higher volatility of 29.26% compared to Moderna, Inc. (MRNA) at 18.74%. This indicates that NVAX's price experiences larger fluctuations and is considered to be riskier than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Novavax, Inc. and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.